Encycle’s technology has been thoroughly explored and validated through collaborations with several entities, including AstraZeneca, GlaxoSmithKline, Merck and Pfizer, along with the Universities of Toronto and Sherbrooke. These collaborations have resulted in a large amount of empirical data, which have been exploited to elucidate quantitative relationships between nacellin structure, membrane permeability and oral bioavailability. Moreover, Encycle has created a library of >4,000 discrete nacellins, which has been screened by our scientists and by a variety of third parties.

We welcome additional opportunities to screen our library against targets of interest, particularly those intractable to small molecules.

Encycle is currently advancing two independent drug discovery and development programs. Our lead program is focused on the IND-enabling development of an orally bioavailable clinical candidate (ET3764), which inhibits integrin alpha-4-beta-7 as a means to treat of inflammatory bowel disease and other inflammatory disorders, whereas the secondary program involves the discovery of inhibitors of selected peptidyl-prolyl isomerases.

Non-biologic modulators of integrin alpha-4-beta-7 have been pursued for years, however low molecular weight entities that are both absorbed from the gut following oral administration and demonstrate appropriate selectivity for the protein have been elusive. Encycle’s ET3764 “threads this needle” and exhibit outstanding results in several in vivo efficacy and pharmacodynamics models.